touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs)’ (LBA-4) was presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
- What are the limitations of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia? (0:17)
- Could you tell us a little about asciminib and its mechanism of action? (2:45)
- What were the aims and design of the ASCEMBL study? (5:37)
- What were the efficacy and safety findings of the ASCEMBL study? (7:15)
- What will be the next steps in the clinical development of asciminib? (8:52)
Speaker Disclosures: Prof. Andreas Hochhaus has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
Share this Video
Related Videos In Leukaemia
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home messages of his award presentation, which focused on Philadelphia-positive acute lymphoblastic leukaemia research. The presentation […]
Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia
The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL. The […]
Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!